Central Nervous System
Cerevance raises $47m to fund Phase III trial for lead Parkinson’s therapy
US-based Cerevance has secured $47m in Series B-1 extension funding to finance the upcoming Phase III trial for its lead…
Alzheimer’s trial doses patients with stem cell treatment directly to brain
California-based Regeneration Biomedical has dosed the first patient has been dosed in a first-in-human trial of its autologous stem cell…
Actinogen finishes enrolling patients in depression therapy trial
Australian biotechnology company Actinogen Medical has finished enrolling subjects in the Phase IIa XanaCIDD clinical trial of Xanamem for treating…
Cerevel reports positive data from Phase III Parkinson’s treatment trial
Cerevel Therapeutics has reported positive topline results from its Phase III TEMPO-3 clinical trial evaluating a once-a-day dose of tavapadon…
AAN 2024: new pooled data highlights efficacy of Axsome Therapeutics’s AXS-07
On 15 April, at the American Academy of Neurology (AAN) 2024, Axsome Therapeutics presented new pooled data from two Phase…
Hyperfine starts enrolment in portable imaging workflow study
US-based health technology company Hyperfine has enrolled the first patient in the clinical workflow study of its US Food and…
AAN 2024: AbbVie highlights long-term safety of atogepant in migraine prevention
At the American Academy of Neurology (AAN) 2024, AbbVie highlighted the long-term safety data of Qulipta (atogepant) for the preventive…
Bayer and AskBio report data from Parkinson’s disease therapy trial
Bayer and its subsidiary Asklepios BioPharmaceutical (AskBio) have reported data from an 18-month Phase Ib clinical trial of a gene…
Actinogen treats first subject in Alzheimer’s disease therapy trial
Australian biotechnology company Actinogen Medical has treated the first subject in the XanaMIA Phase IIb clinical trial of Xanamem in…
FDA halts Neumora’s schizophrenia drug trial over convulsions in rabbits
The US Food and Drug Administration (FDA) has placed a clinical hold on the Phase I trial of Neumora Therapeutics’…
